Transfusion avoidance in myelodysplastic neoplasms
EA Griffiths - Current Opinion in Hematology, 2024 - journals.lww.com
Transfusion avoidance in myelodysplastic neoplasms : Current Opinion in Hematology
Transfusion avoidance in myelodysplastic neoplasms : Current Opinion in Hematology Log in or …
Transfusion avoidance in myelodysplastic neoplasms : Current Opinion in Hematology Log in or …
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
M Molica, M Rossi - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction In patients with myelodysplastic syndromes (MDS), anemia is prevalent
affecting 80%–85% of low-risk (LR-MDS) patients, with 40% eventually requiring red blood …
affecting 80%–85% of low-risk (LR-MDS) patients, with 40% eventually requiring red blood …
[HTML][HTML] Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database …
LA Andritsos, A McBride, D Tang, V Barghout… - Leukemia Research, 2025 - Elsevier
Myelodysplastic syndromes (MDS) are associated with anemia and the need for blood
transfusions. In clinical trials, luspatercept reduced transfusion dependency among patients …
transfusions. In clinical trials, luspatercept reduced transfusion dependency among patients …
[HTML][HTML] Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
A Consagra, L Lanino, NH Al Ali, L Aguirre… - …, 2025 - pmc.ncbi.nlm.nih.gov
We explored the impact of luspatercept therapy on overall survival (OS) and possible
predictors of response in low‐risk (LR) myelodysplastic syndrome (MDS) patients. We …
predictors of response in low‐risk (LR) myelodysplastic syndrome (MDS) patients. We …
Classification update and application interpretation of myelodysplastic syndromes
T Hongyan - J Clin Hematol, 2023 - lcxyen.whuhzzs.com
In 2022, the 5th edition of the World Health Organization Classification of Hematolymphoid
Tumors: Myeloid and Histiocytic/Dendritic Neoplasms (WHO 2022) and International …
Tumors: Myeloid and Histiocytic/Dendritic Neoplasms (WHO 2022) and International …
Neueste Erkenntnisse zum myelodysplastischen Syndrom
V Petzer, D Wolf - TumorDiagnostik & Therapie, 2024 - thieme-connect.com
Neuerungen–Klassifikation und Prognose Die WHO-2016-Klassifikation wurde durch die
ICC und die Klassifikation der WHO 2022 abgelöst. Die beiden Klassifikationen weisen viele …
ICC und die Klassifikation der WHO 2022 abgelöst. Die beiden Klassifikationen weisen viele …
[인용][C] Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough
Ineffective erythropoiesis remains the principal source of diseaserelated symptoms and
morbidity in myelodysplastic syndromes (MDS), resulting in symptomatic anemia, red blood …
morbidity in myelodysplastic syndromes (MDS), resulting in symptomatic anemia, red blood …